Adaptin Bio Receives First IRB Approval for Novel Brain Cancer Immunotherapy APTN-101 Phase 1 Trial
Key Insights
The Preston Robert Tisch Brain Tumor Center (search) granted the first IRB approval for APTN-101's Phase 1 clinical trial in glioblastoma multiforme (search), enabling patient recruitment to begin.
APTN-101 is a Brain Bispecific T cell Engager (search) (BRiTE) that demonstrated compelling anti-tumor activity and favorable safety profile in preclinical studies conducted by Duke University (search) scientists.
The therapy addresses the critical challenge of the blood-brain barrier by enabling efficient delivery of immune-engaging biologics to brain tumors.
Adaptin Bio (search) has achieved a significant regulatory milestone with the Preston Robert Tisch Brain Tumor Center (search) granting the first Institutional Review Board (IRB) approval for its Phase 1 first-in-human clinical trial of APTN-101 in glioblastoma multiforme (search) (GBM (search)). This approval follows the U.S. Food and Drug Administration's acceptance of the company's Investigational New Drug (IND) application and enables patient recruitment to commence.
"Following the successful preclinical development and acceptance of our Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA), we are extremely pleased to receive our first IRB approval for APTN-101's Phase I clinical trial," said Michael J. Roberts, Ph.D., Chief Executive Officer of Adaptin Bio (search). "This represents a major inflection point for our lead program and validates the translation readiness of our targeted bispecific antibody platform."
Addressing Critical Unmet Medical Need
Glioblastoma multiforme (search), classified as a World Health Organization (WHO) Grade IV malignant glioma (search), represents the most aggressive and lethal primary brain tumor (search). Despite decades of research, standard-of-care treatment consisting of surgical resection followed by radiation and chemotherapy remains largely palliative, with median survival of approximately 14-16 months and five-year survival rates below 10%. More than 12,000 new cases are diagnosed annually in the United States alone, underscoring the urgent unmet medical need for innovative therapeutic approaches.
A primary obstacle to progress in GBM (search) and other central nervous system (CNS) diseases is the blood-brain barrier (BBB), which prevents most biologics and immune therapies from reaching therapeutic concentrations within the brain, severely limiting their clinical efficacy.
Novel BRiTE Platform Technology
Adaptin's BRiTE (Brain Bispecific T cell Engager (search)) platform is designed to overcome this fundamental limitation by enabling efficient and selective delivery of immune-engaging biologics across the BBB. APTN-101 leverages this platform to transport a potent T-cell-redirecting bispecific antibody into the brain, where it can recruit and activate cytotoxic T cells directly at the tumor site.
The novel approach leverages the enhanced "hitchhiking" capabilities of manipulated immune cells to deliver therapeutic agents directly to brain tumors. By enabling immune effector cells to penetrate the CNS and engage malignant cells in situ, APTN-101 is designed to address both the immune-privileged nature of the brain and the infiltrative biology of GBM (search), offering the potential for deeper, more durable anti-tumor responses than existing therapies.
Promising Preclinical Results
In collaboration with Duke University (search) investigators, the inventors of the BRiTE platform, APTN-101 demonstrated compelling anti-tumor activity and a favorable safety profile in multiple preclinical models. The therapy showed high specificity for EGFRvIII (search)-expressing glioma cells, dose-responsive efficacy against diverse patient-derived glioma cell lines, and dose-response efficacy with a favorable safety profile observed by Duke University scientists.
Broader Market Potential
Beyond glioblastoma, Adaptin believes its BBB-penetrant immune delivery approach has broad applicability across multiple CNS oncology and neurology indications, representing estimated billion-dollar-plus market opportunities. The global glioma treatment market alone is projected to reach approximately $4.4 billion, with significant expansion potential as effective targeted and immunotherapeutic strategies become clinically viable.
Adaptin plans to leverage the BRiTE platform to build a pipeline of brain-directed immunotherapies aimed at transforming outcomes for patients with currently intractable CNS diseases. The company's proprietary technology was developed by researchers at the Department of Neurosurgery at Duke University (search), and other indications are being considered for future studies.